Relay Therapeutics
RLAY
208 hedge funds and large institutions have $592M invested in Relay Therapeutics in 2025 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 73 increasing their positions, 55 reducing their positions, and 34 closing their positions.
35% more capital invested
Capital invested by funds: $439M → $592M (+$153M)
33% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 55
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
1.03% more ownership
Funds ownership: 98.69% → 99.71% (+1%)
6% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 34
0% more funds holding
Funds holding: 207 → 208 (+1)
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $128K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$39.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.79M |
| 3 |
CC
Casdin Capital
New York
|
+$6.84M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$2.54M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$11.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.11M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.03M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$5.55M |
| 5 |
Millennium Management
New York
|
-$3.19M |
RLAY Hedge Fund Activity: Q2 2025 in Review
208 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q2 2025, worth a combined $592M — up 35% from $439M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RLAY positions and 34 closed out — a net gain of 2 holders — while 73 added to existing stakes and 55 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $39.7M. The largest seller was Norges Bank, cutting an estimated $11.3M.
- 208 institutional investors held Relay Therapeutics (RLAY) as of Q2 2025, up from 207 in Q1 2025.
- Funds reported $592M of Relay Therapeutics stock for Q2 2025, up 35% quarter-over-quarter.
- 36 funds opened new Relay Therapeutics positions in Q2 2025 and 34 closed out, a net change of +2 holders.
- The largest Relay Therapeutics buyer in Q2 2025 was Commodore Capital, an estimated $39.7M added.
- The largest Relay Therapeutics seller in Q2 2025 was Norges Bank, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2025.